Townsend & Associates’s Amgen AMGN Stock Holding History

Townsend & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-597	Closed	-$104K	–	165
2017 Q4	$104K	Buy	+597	New	+$106K	0.09%	100

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Townsend & Associates's AMGN Position: Q1 2018 in Review

Townsend & Associates sold out of Amgen (AMGN) in Q1 2018, closing a stake of 597 shares — an estimated $104K sold.

Townsend & Associates first reported a position in AMGN in Q4 2017 and held it in 1 quarter. The position peaked at $104K in Q4 2017. 1,749 funds tracked by Wall St. Rank hold AMGN as of Q1 2018.

Townsend & Associates reported no remaining Amgen position as of Q1 2018 after selling out during the quarter.
Townsend & Associates sold 597 Amgen shares in Q1 2018, an estimated $104K.
Townsend & Associates first reported a position in Amgen in Q4 2017 and held it in 1 quarter.
Townsend & Associates's Amgen position peaked at $104K in Q4 2017.
1,749 funds tracked by Wall St. Rank held Amgen as of Q1 2018.

Based on Townsend & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.